Analysis of risk genes associated with disulfidptosis-related myocardial ischemia-reperfusion injury

Abstract:

Objective To select genes associated with disulfidptosis-related myocardial ischemia-reperfusion injury（MIRI），and to explore their possible pathways of action.Methods We selected differentially expressed genes associated with MIRI between the 24 h group and the control group with the use of the limma R package； performed functional enrichment analysis on the genes through the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases with the use of the clusterProfiler R package；conducted enrichment analysis based on disulfidptosis-related gene set and GSE160516 expression data using the ssgsea method of the GSVA R package，and identified the expression of disulfidptosis-related genes in myocardial ischemia-reperfusion using a Venn diagram；calculated the correlations between disulfidptosis-related genes and genes associated with apoptosis factors，mitochondria，ferroptosis，and inflammation using the corr. test of the psych R package，and generated a heatmap； and clustered the expression patterns of MIRI transcriptome data at different time points using the Mfuzz R package，and identified time series-related differentially expressed disulfidptosis-related genes using a Venn diagram.Results A total of 17 differentially expressed disulfidptosis-related genes were determined in this study. Through correlation analysis of disulfidptosis-related genes and genes associated with inflammation，apoptosis，ferroptosis，and mitochondria as well as analysis of time series-related differentially expressed genes associated with disulfidptosis during myocardial ischemia-reperfusion，we finally identified the specific expression of disulfidptosis-related Flna，Myl6，and Tln1 genes at different time points pf MIRI.Conclusion The Flna，Myl6，and Tln1 gens may play crucial roles in MIRI，and these disulfidptosis-related genes are closely associated with mitochondria-related genes，which can be screening indicators for risk factors in patients with MIRI.